ReviewZeitschrift fur Rheumatologie2026
[Evolving management of SARD-ILD : Current challenges and emerging treatment options for rheumatoid-associated interstitial lung diseases].
Review in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic rheumatic diseases with interstitial lung disease (SARD-ILD) are often associated with progressive pulmonary fibrosis (PPF), characterised by increasing respiratory symptoms, progressive loss of lung function, and an unfavourable prognosis. Currently available therapies, including glucocorticoids, immunosuppressants and antifibrotic agents, often have limited efficacy depending on the underlying SARD-ILD, while adverse events limit their use. Therefore, there is a substantial unmet need for effective and well-tolerated treatment options.
objectivesThis review summarises current developments and emerging therapeutic approaches in SARD-ILD and PPF, highlighting their potential relevance for clinical practice. MATERIALS AND
methodsA systematic PubMed search (publications up to mid-2025) using the terms "SARD-ILD", "CTD-ILD", "PPF" and "treatment" identified relevant studies investigating novel therapeutic strategies.
resultsSubstances currently under clinical investigation include nerandomilast, belimumab, admilparant, anifrolumab and inhaled treprostinil. Nerandomilast, a preferential PDE4B inhibitor with antifibrotic and anti-inflammatory properties, demonstrated a reduction in lung function loss and mortality risk with good tolerability in the phase‑3 FIBRONEER-ILD study, potentially representing a turning point in the management of autoimmune-associated ILD.
conclusionPromising results from ongoing clinical studies provide new therapeutic perspectives for SARD-ILD and PPF and may significantly improve prognosis and disease burden in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.